Cliff Asness's URGN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 149,228 shares of UroGen Pharma Ltd. (URGN) worth $5.49 M, representing 0.00% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in URGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 117,508 shares. Largest reduction occurred in Q4 2024, reducing 92,450 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's UroGen Pharma (URGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly UroGen Pharma (URGN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +5,168 | Add 3.59% | 149,228 | $36.80 |
| Q1 2026 | -9,353 | Reduce 6.10% | 144,060 | $17.98 |
| Q4 2025 | -50,778 | Reduce 24.87% | 153,413 | $23.42 |
| Q3 2025 | -27,383 | Reduce 11.82% | 204,191 | $19.95 |
| Q2 2025 | +117,508 | Add 103.02% | 231,574 | $13.70 |
| Q1 2025 | +88,577 | Add 347.51% | 114,066 | $11.06 |
| Q4 2024 | -92,450 | Reduce 78.39% | 25,489 | $10.65 |
| Q3 2024 | +87,649 | Add 289.37% | 117,939 | $12.70 |
| Q2 2024 | -11,972 | Reduce 28.33% | 30,290 | $16.78 |
| Q1 2024 | +23,879 | Add 129.90% | 42,262 | $15.00 |
| Q4 2023 | +18,383 | New Buy | 18,383 | $15.00 |
Cliff Asness's UroGen Pharma Investment FAQs
Cliff Asness first purchased UroGen Pharma Ltd. (URGN) in Q4 2023, acquiring 18,383 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held UroGen Pharma Ltd. (URGN) for 11 quarters since Q4 2023.
Cliff Asness's largest addition to UroGen Pharma Ltd. (URGN) was in Q2 2025, adding 231,574 shares worth $3.17 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 149,228 shares of UroGen Pharma Ltd. (URGN), valued at approximately $5.49 M.
As of the Q2 2026 filing, UroGen Pharma Ltd. (URGN) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in UroGen Pharma Ltd. (URGN) was 231,574 shares, as reported at the end of Q2 2025.